Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25594520 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL25605193 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL18294595 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL19051014 | 1.00 | FGF1 (0.33) | FGF1 | |
| SCHEMBL18755701 | 0.98 | FGF1 (0.36) | FGF1 | |
| SCHEMBL12289342 | 0.98 | FGF1 (0.36) | FGF1 | |
| SCHEMBL18755374 | 0.98 | FGF1 (0.36) | FGF1 | |
| SCHEMBL18755371 | 0.98 | FGF1 (0.36) | FGF1 | |
| SCHEMBL12441863 | 0.98 | FGF1 (0.36) | FGF1 | |
| SCHEMBL18755694 | 0.98 | FGF1 (0.36) | FGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230332143-A1 | RNA-Editing Oligonucleotides and Uses Thereof | KORRO BIO, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230295614-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL) | KORRO BIO, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230174989-A1 | Methods and Compositions for the ADAR-Mediated Editing of ABCA4 | KORRO BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230332143-A1 | RNA-Editing Oligonucleotides and Uses Thereof | ADAR, NSUN3, NSUN2 | FGF1 4737/4885 |
| US-20230174989-A1 | Methods and Compositions for the ADAR-Mediated Editing of ABCA4 | ADAR, ABCB4, ADA | FGF1 4396/4885 |
| US-20230295614-A1 | METHODS AND COMPOSITIONS FOR THE ADAR-MEDIATED EDITING OF ARGININOSUCCINATE LYASE (ASL) | ADAR, ADA, ASS1 | FGF1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.